--- title: "CalciMedica (CALC) news: offering" url: "https://aibio.space/companies/calcimedica/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CALC offering news: CalciMedica files to sell up to $25,000,000 of stock through at-the-market program. CalciMedica, Inc. (NASDAQ: CALC), United States." --- CALC CalciMedica, Inc. NASDAQ · United States # CalciMedica (CALC) news CALC offering news Financings · 2026-09-30 ## [CalciMedica files to sell up to $25,000,000 of stock through at-the-market program](https://aibio.space/news/calcimedica-files-sell-up-25-000-000-stock-through-market-program/) CalciMedica filed a prospectus supplement on September 30, 2026 for up to $25,000,000 of stock, sold through H.C. Wainwright & Co., LLC as sales agent for a 3.0% commission. The company has stopped one Phase 2 trial of its lead drug and now plans a Phase 2b step first. ## Latest CalciMedica news 1. 2026-06-24 Financings [CalciMedica agrees to private placement with expected upfront gross proceeds of about $15.0 million](https://aibio.space/news/calcimedica-agrees-private-placement-expected-upfront-gross-proceeds/) Investors agreed to buy 18,673,429 units at $0.8033 or $0.8032. Series A and B warrants could add up to approximately $34 million if fully exercised for cash. Closing is expected on or about June 25, 2026. 2. 2026-06-23 Debt Financing [CalciMedica pushes Avenue loan maturity to 2029 and cuts warrant price](https://aibio.space/news/calcimedica-pushes-avenue-loan-maturity-2029-cuts-warrant-price/) Avenue Venture Opportunities Fund II, L.P. is the lender on a $10,000,000 loan. The amendment moves maturity to September 1, 2029, expands the lender's conversion right to up to $3,000,000 and cuts the warrant price to $1.00. 3. 2025-03-05 Debt Financing [CalciMedica signs loan agreement for up to $32.5 million, funds $10 million at close](https://aibio.space/news/calcimedica-signs-loan-agreement-up-32-5-million-funds-10-million/) The Avenue Venture Opportunities Fund II loan matures September 1, 2028 and carries a warrant for 641,163 shares at $2.32. CalciMedica says the first tranche extends its cash runway to the middle of 2026. ## CalciMedica at a glance - **Ticker**: CALC - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $18.6 million ### Related companies - [Kura Oncology](https://aibio.space/companies/kura-oncology/) NASDAQ: KURA - [Attovia Therapeutics](https://aibio.space/companies/attovia-therapeutics/) NASDAQ: ATTO - [LadRx](https://aibio.space/companies/ladrx/) OTC: LADX - [INmune Bio](https://aibio.space/companies/inmune-bio/) NASDAQ: INMB - [Summit Therapeutics](https://aibio.space/companies/summit-therapeutics/) NASDAQ: SMMT - [Carisma Therapeutics](https://aibio.space/companies/carisma-therapeutics/) OTC: CARM - [Fractyl Health](https://aibio.space/companies/fractyl-health/) NASDAQ: GUTS - [Absci](https://aibio.space/companies/absci/) NASDAQ: ABSI ### Also on NASDAQ - [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) LSTA - [XBiotech](https://aibio.space/companies/xbiotech/) XBIT - [NovoCure](https://aibio.space/companies/novocure/) NVCR - [Lantern Pharma](https://aibio.space/companies/lantern-pharma/) LTRN - [Fortress Biotech](https://aibio.space/companies/fortress-biotech/) FBIO - [Voyager Therapeutics](https://aibio.space/companies/voyager-therapeutics/) VYGR ## CalciMedica annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$15.2 million](https://www.sec.gov/Archives/edgar/data/1534133/000119312526088147/) | [$14.5 million](https://www.sec.gov/Archives/edgar/data/1534133/000119312526088147/) | | Net income (loss) | [-$29.6 million](https://www.sec.gov/Archives/edgar/data/1534133/000119312526088147/) | [-$13.7 million](https://www.sec.gov/Archives/edgar/data/1534133/000119312526088147/) | | Cash from operations | [-$21.2 million](https://www.sec.gov/Archives/edgar/data/1534133/000119312526088147/) | [-$21.1 million](https://www.sec.gov/Archives/edgar/data/1534133/000119312526088147/) | | Cash and equivalents | [$11.5 million](https://www.sec.gov/Archives/edgar/data/1534133/000119312526344689/) | [$7.9 million](https://www.sec.gov/Archives/edgar/data/1534133/000119312526088147/) | | Short-term investments | [$1.5 million](https://www.sec.gov/Archives/edgar/data/1534133/000119312526344689/) | [$10.7 million](https://www.sec.gov/Archives/edgar/data/1534133/000119312526088147/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $18.6 million, plus short-term investments of $0, $18.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about CalciMedica Has CalciMedica raised money recently? Our latest story on this, dated Sep 30, 2026: "CalciMedica files to sell up to $25,000,000 of stock through at-the-market program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/calcimedica-files-sell-up-25-000-000-stock-through-market-program/). What is the ticker symbol of CalciMedica? CalciMedica, Inc. trades under the ticker CALC on NASDAQ. Where is CalciMedica listed? CalciMedica, Inc. is listed on NASDAQ. What is the SEC CIK of CalciMedica? The SEC Central Index Key (CIK) for CalciMedica, Inc. is 1534133. Its filings are on SEC EDGAR. How many shares does CalciMedica have outstanding? 34,141,460 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is CalciMedica listed under? Our directory records CalciMedica, Inc. under United States. What does CalciMedica do? Our directory classifies CalciMedica, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of CalciMedica? The ISIN recorded for CalciMedica, Inc. is US38942Q3011. Does aibio.space cover CalciMedica? aibio.space lists CalciMedica, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is CalciMedica incorporated? SEC records list its state or country of incorporation as DE. Is CalciMedica profitable? CalciMedica, Inc. reported a net loss of $29.6 million for the fiscal year ended Dec 31, 2025, and used $21.2 million of cash in operations, per its annual report to the SEC. How much does CalciMedica spend on research and development? $15.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does CalciMedica have? $18.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest CalciMedica (CALC) stock news? Our latest story on CalciMedica, dated Sep 30, 2026: "CalciMedica files to sell up to $25,000,000 of stock through at-the-market program". CalciMedica filed a prospectus supplement on September 30, 2026 for up to $25,000,000 of stock, sold through H.C. Wainwright & Co., LLC as sales agent for a 3.0% commission. The company has stopped one Phase 2 trial of its lead drug and now plans a Phase 2b step first. [Source](https://aibio.space/news/calcimedica-files-sell-up-25-000-000-stock-through-market-program/). Does CalciMedica have debt, a term loan or convertible notes? Our latest debt story, dated Jun 23, 2026: "CalciMedica pushes Avenue loan maturity to 2029 and cuts warrant price". Avenue Venture Opportunities Fund II, L.P. is the lender on a $10,000,000 loan. The amendment moves maturity to September 1, 2029, expands the lender's conversion right to up to $3,000,000 and cuts the warrant price to $1.00. [Source](https://aibio.space/news/calcimedica-pushes-avenue-loan-maturity-2029-cuts-warrant-price/). ## Investor discussion: CalciMedica Members talk about CalciMedica (CALC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at CalciMedica, newest first. Each line links the filing it comes from. 1. 2026-09-30 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1534133/000119312526409041/d145394d424b5.htm) 2. 2026-09-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1534133/000119312526393034/d166013d8k.htm) 3. 2026-09-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1534133/000119312526379419/d133027d8k.htm) 4. 2026-08-27 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1534133/000119312526369713/d165361d8k.htm) 5. 2026-08-20 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1534133/000119312526357258/d434771d8k.htm) 6. 2026-07-23 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1534133/000119312526314085/d28288ddef14a.htm) 7. 2026-07-13 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1534133/000119312526302112/d28288dpre14a.htm) 8. 2026-06-24 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1534133/000119312526280223/d40651d8k.htm) 9. 2026-03-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1534133/000119312526114096/d101411d8k.htm) 10. 2025-11-06 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1534133/000119312525269496/d65924d424b5.htm) 11. 2025-08-12 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1534133/000095017025107334/ck0001534133-20250630.htm) 12. 2025-06-06 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1534133/000119312525136297/d901981d8k.htm) 13. 2025-03-05 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1534133/000119312525046225/d940326dex991.htm) 14. 2024-12-20 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1534133/000119312524283094/d824183d424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CALC on TradingView](https://www.tradingview.com/symbols/NASDAQ-CALC/). ## SEC filings and registration - **SEC name**: CalciMedica, Inc. - **CIK**: 1534133 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CALC (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 505 COAST BOULEVARD SOUTH, LA JOLLA, CA, 92037 - **Phone**: 858-952-5500 - **Shares outstanding**: 34,141,460 as of 2026-08-05 (10-Q filed 2026-08-11) - **Former names**: CalciMedica, Inc. /DE/; GRAYBUG VISION, INC.; GRAYBUG, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1534133/000119312526424203/d305911d8k.htm) filed 2026-10-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1534133/000119312526409049/d39303d8k.htm) filed 2026-09-30 - [424B5](https://www.sec.gov/Archives/edgar/data/1534133/000119312526409041/d145394d424b5.htm) filed 2026-09-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1534133/000119312526393034/d166013d8k.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1534133/000119312526379419/d133027d8k.htm) filed 2026-09-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1534133/000119312526369713/d165361d8k.htm) filed 2026-08-27 - [8-K](https://www.sec.gov/Archives/edgar/data/1534133/000119312526357258/d434771d8k.htm) filed 2026-08-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/1534133/000119312526344689/ck0001534133-20260630.htm) filed 2026-08-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001534133), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details CalciMedica, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CALC, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: CalciMedica, Inc. - **Ticker**: CALC - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US38942Q3011 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CALC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/calcimedica/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "CalciMedica (CALC) news: offering", 2026-10-31, https://aibio.space/companies/calcimedica/